NCT06245629View on ClinicalTrials.gov

Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

November 24, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

November 30, 2025

Conditions
Myeloma Multiple
Interventions
DRUG

Bortezomib-bendamustine-melphalan

The aim of this retrospective cohort study is to evaluate the efficacy and safety of the conditioning regimen BBM compared to HDM in the setting of relapsed multiple myeloma.

Trial Locations (1)

Unknown

RECRUITING

Akademiska sjukhuset, Uppsala

All Listed Sponsors
collaborator

Uppsala County Council, Sweden

OTHER_GOV

collaborator

Dalarna County Council, Sweden

OTHER

lead

Uppsala University

OTHER